AI assistant
Sending…
Monopar Therapeutics — Director's Dealing 2024
Jun 18, 2024
32883_dirs_2024-06-17_9e1b3cb5-608f-40d6-922d-5bdf0eec91dd.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Monopar Therapeutics (MNPR)
CIK: 0001645469
Period of Report: 2024-06-13
Reporting Person: Cittadine Andrew (Chief Operating Officer)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2024-06-13 | Common Stock | P | 12000 | $0.91 | Acquired | 129624 | Direct |
| 2024-06-14 | Common Stock | P | 12000 | $0.9313 | Acquired | 141624 | Direct |
| 2024-06-17 | Common Stock | P | 12000 | $0.89990 | Acquired | 153624 | Direct |
Footnotes
F1: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.9100 to $0.93994, inclusive. The reporting person undertakes to provide to Monopar Therapeutics, any security holder of Monopar Therapeutics, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in the preceding sentence.